Evidence map›Paper›PMID 32664486›Full record

ArticleVaccines2020

A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity and Safety of a Bivalent DNA Vaccine for Hemorrhagic Fever with Renal Syndrome Delivered by Intramuscular Electroporation.

Jay Hooper, K M Paolino, K Mills, S Kwilas, M Josleyn, M Cohen, B Somerville, M Wisniewski, S Norris, B Hill and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
0.5field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Generation and Characterization of the Human Anti-HTNV Antibody KJJ4.International journal of molecular sciences · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Jay HooperVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
K M PaolinoClinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
K MillsClinical Trials Center, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
S KwilasVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
M JosleynVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
M CohenVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
B SomervilleVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
M WisniewskiVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
S NorrisVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
B HillVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
M Sanchez-LockhartVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
D HannamanIchor Medical Systems, Inc., San Diego, CA 92121, USA.
C S SchmaljohnVirology Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
United States Army Medical Research Institute of Infectious Diseases · USWalter Reed Army Institute of Research · USIchor Medical Systems (United States) · US

Funding

US Army Military Infectious Disease Research Program, Area T Lethal Viruses
6 · The paper itself

Abstract

Hantaan virus (HTNV) and Puumala virus (PUUV) are pathogenic hantaviruses found in Asia and Europe, respectively. DNA vaccines targeting the envelope glycoproteins of these viruses have been constructed and found to elicit neutralizing antibodies when delivered to humans by various technologies including intramuscular electroporation. Here, we report findings from a Phase 2a clinical trial of a combined HTNV/PUUV DNA vaccine delivered at varying doses and administration schedules using the Ichor Medical Systems TriGrid intramuscular electroporation delivery technology. The study was designed to characterize the effects of DNA vaccine dose and number of administrations on the frequency and magnitude of immunological response. Subjects (

Indexed as

DNA vaccineelectroporationhantavirushemorrhagic fever with renal syndrome

Identifiers

PMID32664486
PMCPMC7565952
OpenAlexW3041828293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.